Agenus Stock Soars 83%, but $255 Million of Its $340 Million Lifeline Is Still Conditional
Agenus Inc. shares closed 82.7% higher at $6.12 on Monday after the cancer-drug developer unveiled financing of up to $340 million for a pivotal colon-cancer study. The stock reached $8.70 and roughly 174 million shares changed hands. The regular U.S. session had not opened at the dateline; Nasdaq was scheduled to trade normally on Tuesday.